These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

174 related articles for article (PubMed ID: 31463367)

  • 21. Interferon-beta expression and type I interferon receptor signaling of hepatocytes prevent hepatic necrosis and virus dissemination in Coxsackievirus B3-infected mice.
    Koestner W; Spanier J; Klause T; Tegtmeyer PK; Becker J; Herder V; Borst K; Todt D; Lienenklaus S; Gerhauser I; Detje CN; Geffers R; Langereis MA; Vondran FWR; Yuan Q; van Kuppeveld FJM; Ott M; Staeheli P; Steinmann E; Baumgärtner W; Wacker F; Kalinke U
    PLoS Pathog; 2018 Aug; 14(8):e1007235. PubMed ID: 30075026
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Combined targeting of EGFR/HER promotes anti-tumor efficacy in subsets of KRAS mutant lung cancer resistant to single EGFR blockade.
    Umelo IA; De Wever O; Kronenberger P; Van Deun J; Noor A; Singh K; Teugels E; Chen G; Bracke M; De Grève J
    Oncotarget; 2015 Aug; 6(24):20132-44. PubMed ID: 25992771
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Detection and Analysis of EGFR and KRAS Mutation with Lung Adenocarcinoma].
    Zhang H; Yang X; Qin N; Li X; Yang H; Nong J; Lv J; Wu Y; Zhang Q; Zhang X; Wang J; Zhou L; Zhang S
    Zhongguo Fei Ai Za Zhi; 2015 Nov; 18(11):686-90. PubMed ID: 26582224
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Mutational status of
    Ku BM; Bae YH; Koh J; Sun JM; Lee SH; Ahn JS; Park K; Ahn MJ
    Oncotarget; 2017 Sep; 8(40):67526-67537. PubMed ID: 28978051
    [No Abstract]   [Full Text] [Related]  

  • 25. Emergence of a Large-Plaque Variant in Mice Infected with Coxsackievirus B3.
    Wang Y; Pfeiffer JK
    mBio; 2016 Mar; 7(2):e00119. PubMed ID: 27025249
    [TBL] [Abstract][Full Text] [Related]  

  • 26.
    Fu Q; Gao L; Fu X; Meng Q; Lu Z
    J Microbiol Biotechnol; 2019 Aug; 29(8):1230-1239. PubMed ID: 31370111
    [No Abstract]   [Full Text] [Related]  

  • 27. NOD2 (Nucleotide-Binding Oligomerization Domain 2) Is a Major Pathogenic Mediator of Coxsackievirus B3-Induced Myocarditis.
    Tschöpe C; Müller I; Xia Y; Savvatis K; Pappritz K; Pinkert S; Lassner D; Heimesaat MM; Spillmann F; Miteva K; Bereswill S; Schultheiss HP; Fechner H; Pieske B; Kühl U; Van Linthout S
    Circ Heart Fail; 2017 Sep; 10(9):. PubMed ID: 28912259
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Activation of AMPK restricts coxsackievirus B3 replication by inhibiting lipid accumulation.
    Xie W; Wang L; Dai Q; Yu H; He X; Xiong J; Sheng H; Zhang D; Xin R; Qi Y; Hu F; Guo S; Zhang K
    J Mol Cell Cardiol; 2015 Aug; 85():155-67. PubMed ID: 26055448
    [TBL] [Abstract][Full Text] [Related]  

  • 29. An Inhibitor of the Pleckstrin Homology Domain of CNK1 Selectively Blocks the Growth of Mutant KRAS Cells and Tumors.
    Indarte M; Puentes R; Maruggi M; Ihle NT; Grandjean G; Scott M; Ahmed Z; Meuillet EJ; Zang S; Lemos R; Du-Cuny L; Layng FIAL; Correa RG; Bankston LA; Liddington RC; Kirkpatrick L; Powis G
    Cancer Res; 2019 Jun; 79(12):3100-3111. PubMed ID: 31040156
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Screening for tumor suppressors: Loss of ephrin receptor A2 cooperates with oncogenic KRas in promoting lung adenocarcinoma.
    Yeddula N; Xia Y; Ke E; Beumer J; Verma IM
    Proc Natl Acad Sci U S A; 2015 Nov; 112(47):E6476-85. PubMed ID: 26542681
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Impact of Concurrent PIK3CA Mutations on Response to EGFR Tyrosine Kinase Inhibition in EGFR-Mutant Lung Cancers and on Prognosis in Oncogene-Driven Lung Adenocarcinomas.
    Eng J; Woo KM; Sima CS; Plodkowski A; Hellmann MD; Chaft JE; Kris MG; Arcila ME; Ladanyi M; Drilon A
    J Thorac Oncol; 2015 Dec; 10(12):1713-9. PubMed ID: 26334752
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The PI3K/AKT pathway promotes gefitinib resistance in mutant KRAS lung adenocarcinoma by a deacetylase-dependent mechanism.
    Jeannot V; Busser B; Brambilla E; Wislez M; Robin B; Cadranel J; Coll JL; Hurbin A
    Int J Cancer; 2014 Jun; 134(11):2560-71. PubMed ID: 24374738
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Synergy of WEE1 and mTOR Inhibition in Mutant
    Hai J; Liu S; Bufe L; Do K; Chen T; Wang X; Ng C; Li S; Tsao MS; Shapiro GI; Wong KK
    Clin Cancer Res; 2017 Nov; 23(22):6993-7005. PubMed ID: 28821559
    [No Abstract]   [Full Text] [Related]  

  • 34. Prognostic value of the KRAS G12V mutation in 841 surgically resected Caucasian lung adenocarcinoma cases.
    Renaud S; Falcoz PE; Schaëffer M; Guenot D; Romain B; Olland A; Reeb J; Santelmo N; Chenard MP; Legrain M; Voegeli AC; Beau-Faller M; Massard G
    Br J Cancer; 2015 Oct; 113(8):1206-15. PubMed ID: 26372703
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The non-small cell lung cancer EGFR extracellular domain mutation, M277E, is oncogenic and drug-sensitive.
    Yu S; Zhang Y; Pan Y; Cheng C; Sun Y; Chen H
    Onco Targets Ther; 2017; 10():4507-4515. PubMed ID: 28979142
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Protein kinase B/Akt regulates coxsackievirus B3 replication through a mechanism which is not caspase dependent.
    Esfandiarei M; Luo H; Yanagawa B; Suarez A; Dabiri D; Zhang J; McManus BM
    J Virol; 2004 Apr; 78(8):4289-98. PubMed ID: 15047842
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Prospective Validation of Rapid Plasma Genotyping for the Detection of EGFR and KRAS Mutations in Advanced Lung Cancer.
    Sacher AG; Paweletz C; Dahlberg SE; Alden RS; O'Connell A; Feeney N; Mach SL; Jänne PA; Oxnard GR
    JAMA Oncol; 2016 Aug; 2(8):1014-22. PubMed ID: 27055085
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Comparison of targeted next-generation sequencing with conventional sequencing for predicting the responsiveness to epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI) therapy in never-smokers with lung adenocarcinoma.
    Han JY; Kim SH; Lee YS; Lee SY; Hwang JA; Kim JY; Yoon SJ; Lee GK
    Lung Cancer; 2014 Aug; 85(2):161-7. PubMed ID: 24857785
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Epidermal growth factor receptor and KRAS mutations in lung adenocarcinoma: a retrospective study of the Lebanese population.
    Fakhruddin N; Mahfouz R; Farhat F; Tfayli A; Abdelkhalik R; Jabbour M; Yehia L; Mahfoud Z; Zaatari G
    Oncol Rep; 2014 Nov; 32(5):2223-9. PubMed ID: 25120214
    [TBL] [Abstract][Full Text] [Related]  

  • 40. KRAS mutant lung cancer cells are differentially responsive to MEK inhibitor due to AKT or STAT3 activation: implication for combinatorial approach.
    Yoon YK; Kim HP; Han SW; Oh DY; Im SA; Bang YJ; Kim TY
    Mol Carcinog; 2010 Apr; 49(4):353-62. PubMed ID: 20358631
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.